{"id":127918,"date":"2021-09-21T14:23:00","date_gmt":"2021-09-21T21:23:00","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2021\/09\/mercks-anti-covid-drug-molnupiravir-moves-to-phase-3-for-prevention"},"modified":"2021-09-21T14:23:00","modified_gmt":"2021-09-21T21:23:00","slug":"mercks-anti-covid-drug-molnupiravir-moves-to-phase-3-for-prevention","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2021\/09\/mercks-anti-covid-drug-molnupiravir-moves-to-phase-3-for-prevention","title":{"rendered":"Merck\u2019s anti-COVID drug molnupiravir moves to phase 3 for prevention"},"content":{"rendered":"<p style=\"padding-right: 20px\"><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/mercks-anti-covid-drug-molnupiravir-moves-to-phase-3-for-prevention.jpg\"><\/a><\/p>\n<p>Merck, known as MSD outside the US and Canada, and Ridgeback Biotherapeutics have announced that its MOV-e-AHEAD study has started to enrol its first participants to test antiviral molnupiravir in post-exposure prophylaxis of COVID-19 infection.<\/p>\n<p>The global study will include approximately 1,332 participants who are 18 years or over and reside in the same household as someone with laboratory-confirmed SARS-CoV-2 infection, has at least one sign or symptom of COVID-19 and has not had those signs and symptoms for more than five days.<\/p>\n<p>Participants will be randomised onto molnupiravir, an investigational oral antiviral therapeutic, or placebo every 12 hours for 5 days. The trial will not look at vaccinated people, those who have had COVID-19 before or anyone showing signs or symptoms of infection.<\/p>\n<p>The MOVe-AHEAD trial will test whether the drug prevents infection in those living in the same household as someone with confirmed COVID-19.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck, known as MSD outside the US and Canada, and Ridgeback Biotherapeutics have announced that its MOV-e-AHEAD study has started to enrol its first participants to test antiviral molnupiravir in post-exposure prophylaxis of COVID-19 infection. The global study will include approximately 1,332 participants who are 18 years or over and reside in the same household [\u2026]<\/p>\n","protected":false},"author":534,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-127918","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/127918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/534"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=127918"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/127918\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=127918"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=127918"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=127918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}